What Eledon Pharmaceuticals does

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, a first-in-class anti-CD40L monoclonal antibody that modulates rather than suppresses the immune system by blocking the CD40/CD40L costimulatory pathway, inhibiting multiple costimulatory receptors including CD40 and CD11, and increasing polarization of lymphocytes into regulatory T cells (Tregs). The company targets the ~100,000-person U.S. kidney transplant waiting list as its primary indication — where standard-of-care calcineurin inhibitors (tacrolimus) drive a 10-12 year average functional lifespan and significant toxicity — and is also developing tegoprubart across islet cell transplantation for Type 1 diabetes (FDA Orphan Drug Designation), liver transplantation (FDA Orphan Drug Designation, March 2026), xenotransplantation programs (kidney via eGenesis; heart via United Therapeutics, MGH, UMD), and a Phase 2-completed ALS program.

Eledon's lead asset has demonstrated differentiated clinical performance versus tacrolimus, including a mean eGFR of 74 versus 61 mL/min/1.73 m² at 18 months in the Phase 2 BESTOW kidney transplant trial and zero biopsy-proven acute rejection events after six months in the tegoprubart arm versus seven in the tacrolimus arm. In an investigator-sponsored islet cell transplant trial at UChicago Medicine, 12 of 12 type 1 diabetes patients achieved insulin independence with mean HbA1c of ~5.4% on a tegoprubart-based regimen. The company is pre-revenue, with no approved products or pricing models; operations are funded through equity financings, including a $50M oversubscribed private placement led by BVF Partners LP (May 2024) and a $50M underwritten public offering led by Leerink Partners and Cantor Fitzgerald (November 2025), with $111.1M in cash, equivalents, and short-term investments as of March 31, 2026, expected to fund operations into Q2 2027.

The business model centers on advancing tegoprubart through clinical development, securing regulatory designations, and building a network of strategic partnerships with transplant centers and biopharma collaborators (NewcelX, eGenesis, United Therapeutics, Mass General, UChicago Medicine) that validate the platform across indications. A planned Phase 3 registrational trial in kidney transplantation is targeted for late 2026 following an FDA End-of-Phase 2 meeting, with future commercial launch envisioned through specialty pharma channels targeting transplant centers. Tegoprubart (formerly AT-1501) originated from research partly funded by Augie's Quest to Cure ALS and is protected by FDA Orphan Drug Designations in two indications, positioning the company as a potential first-mover in the anti-CD40L antibody class for transplantation.

Name

Eledon Pharmaceuticals

Legal name

Eledon Pharmaceuticals, Inc.

Website

https://eledon.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, a first-in-class anti-CD40L monoclonal antibody being advanced across kidney, liver, islet cell, and xenotransplantation indications to address immune-mediated rejection and calcineurin inhibitor toxicity in organ and cellular transplant recipients.

Ownership category

akta.pro rank

Product category

Transplant Immunology Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)

Keywords

• Clinical-stage biopharmaceuticals
• Immunosuppressive antibody therapy
• Organ transplant therapeutics
• Anti-CD40L antibody
• Monoclonal antibody development

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pre-revenue clinical development: Eledon is a clinical-stage biotechnology company with no commercial product revenue. Operations are funded by equity financings (public offerings, private placements) and research collaborations. The company is not yet generating product revenue; tegoprubart is in clinical trials and has not been approved or commercialized.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, an investigational anti-CD40L monoclonal antibody, for the prevention of allograft rejection in organ and cellular transplantation. The lead program targets kidney transplantation (Phase 2 BESTOW completed, Phase 3 planned) with additional programs in islet cell transplantation for Type 1 diabetes, liver transplantation, xenotransplantation, and ALS. The company is pre-revenue and not yet commercially selling any approved product.

Product overview

Eledon Pharmaceuticals is a clinical-stage biotechnology company built around a single lead investigational product, tegoprubart, an anti-CD40L antibody — rather than a platform-plus-modules architecture. Tegoprubart serves as the cornerstone of Eledon's pipeline and is being developed across multiple transplant indications (kidney allotransplantation via the completed Phase 2 BESTOW trial and ongoing Phase 1b/extension studies, islet cell transplantation in Type 1 diabetes with FDA Orphan Drug Designation, liver transplantation with FDA Orphan Drug Designation, and kidney tolerance) as well as xenotransplantation programs (eGenesis-sponsored Phase 1/2/3 kidney study, adult heart under FDA Expanded Access Protocol, and pediatric heart) and a neurodegenerative disease program in amyotrophic lateral sclerosis (ALS). The company's product strategy is to leverage its immunology expertise around the CD40/CD40L pathway to address a single underlying mechanism — immune-mediated rejection and dysregulated immune response — across this portfolio of tegoprubart programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Tegoprubart Tegoprubart is Eledon's lead investigational anti-CD40L monoclonal antibody with high affinity for CD40 Ligand (CD40L/CD154). It blocks the CD40/CD40L co-stimulatory immune pathway, inhibits multiple costimulatory receptors including CD40 and CD11, and increases polarization of lymphocytes into regulatory T cells (Tregs), creating a tolerogenic environment to prevent organ transplant rejection without the lymphopenia associated with many immunosuppressive drugs.
• Tegoprubart — Kidney Transplantation Program Completed global Phase 2 BESTOW trial comparing tegoprubart versus tacrolimus for prevention of rejection in first-time kidney allograft recipients, plus ongoing Phase 1b and Long-Term Extension trials. Participants completing BESTOW are eligible to enroll in an ongoing global open-label extension study evaluating long-term efficacy and safety.
• Tegoprubart — Islet Cell Transplantation Program Investigator-sponsored trials at the University of Chicago evaluating tegoprubart as part of an immunosuppression regimen following islet cell transplantation in Type 1 diabetes patients. Has received U.S. FDA Orphan Drug Designation. A multi-site investigator-sponsored trial is also evaluating tegoprubart in islet cell transplantation in patients with impaired renal function.
• Tegoprubart — Liver Transplantation Program IND-ready liver transplantation program. Tegoprubart received FDA Orphan Drug Designation for preventing allograft rejection in liver transplantation, with Eledon planning to initiate a clinical trial.
• Tegoprubart — Xenotransplantation Programs Xenotransplantation programs include the eGenesis-sponsored Phase 1/2/3 study in kidney xenotransplantation. Additional adult heart procedures have been performed under U.S. FDA Expanded Access Protocol (EAP), and a pediatric heart program is also in development. Tegoprubart has been used in landmark pig kidney transplants at Massachusetts General Hospital and a pig heart transplant at the University of Maryland Medical Center.
• Tegoprubart — Kidney Tolerance Program Massachusetts General Hospital investigator-sponsored trial evaluating tegoprubart in kidney tolerance induction.
• Tegoprubart — ALS (Amyotrophic Lateral Sclerosis) Program Eledon has successfully completed a Phase 2, dose-ranging, biomarker study in amyotrophic lateral sclerosis (ALS). The company is seeking non-equity dilutive financing to advance the program to Phase 3.

Quantifiable outcome

• Mean eGFR of 74 mL/min/1.73 m² for tegoprubart vs. 61 mL/min/1.73 m² for tacrolimus at 18 months in Phase 2 BESTOW kidney transplant trial (p<0.05)
• +4 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• University of Chicago Medicine Transplant InstitutecoreImplementation/ SI/ Consulting Partner · 1 June 2026Investigator-sponsored Phase 2 islet cell transplantation trial of tegoprubart in type 1 diabetes patients at UChicago Medicine Transplant Institute (Dr. Piotr Witkowski). Trial funded by Breakthrough T1D and supported by The Cure Alliance; 12/12 patients achieved insulin independence.
• The Cure AllianceminorGTM or Marketing Partner · 1 June 2026Supported the investigator-initiated Phase 2 islet cell transplant trial of tegoprubart in type 1 diabetes patients at the University of Chicago Medicine Transplant Institute.
• NewcelX Ltd.coreStrategic or Co-development Partner · 1 March 2026NewcelX and Eledon announced a strategic research collaboration to advance the NCEL-101 program for Type 1 Diabetes, integrating Eledon's anti-CD40L monoclonal antibody tegoprubart with NewcelX's stem-cell-derived NCEL-101 islet therapy. The collaboration aims to support durable islet graft survival and streamline regulatory pathways, leveraging extensive transplant experience.
• United TherapeuticscoreStrategic or Co-development Partner · 1 February 2026Eledon is supporting global xenotransplant collaborations with United Therapeutics, providing tegoprubart as the immunosuppression backbone for xenotransplantation programs.
• eGenesiscoreStrategic or Co-development Partner · 1 January 2024eGenesis-sponsored Phase 1/2/3 study of tegoprubart in xenotransplantation (gene-edited pig kidney transplants). Eledon supports eGenesis' pig-to-human kidney xenotransplant program with tegoprubart as the immunosuppression regimen.
• Massachusetts General HospitalcoreImplementation/ SI/ Consulting Partner · 1 January 2024Investigator-sponsored Kidney Tolerance study at Mass. General Hospital; MGH also performed the second gene-edited pig kidney xenotransplant with tegoprubart as the immunosuppression backbone.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Bristol Myers Squibb: BMS markets Nulojix (belatacept), a CD80/CD86 costimulation blocker approved for kidney transplant rejection prophylaxis, making it the only currently approved biologic alternative to calcineurin inhibitors in transplantation and the closest incumbent to tegoprubart's mechanism category.
• Vertex Pharmaceuticals: Vertex acquired Alpine Immune Sciences, a transplant immunology company developing a first-in-class immunomodulator for kidney transplant, in 2024, making it a major pharma competitor with overlapping transplant-immunology ambitions and substantially greater resources.
• Pfizer: Pfizer (legacy Wyeth/Hospira) markets sirolimus/rapamycin and other transplant immunosuppressants, and has a long history in transplant therapeutics — making it a broad incumbent that competes in the same prescriber and patient population tegoprubart would target.
• Sanofi: Sanofi markets CellCept (mycophenolate mofetil), a widely used transplant immunosuppressant, and also acquired Provention Bio for $2.9B. Director Jan Hillson's prior role there highlights Sanofi's deep ties to the transplant and immunology commercial channels Eledon must engage.
• Astellas Pharma: Astellas markets Prograf (tacrolimus), the 30-year standard-of-care immunosuppressant that tegoprubart is being positioned to replace in kidney transplantation. Astellas is the dominant incumbent whose share tegoprubart must take to generate commercial value.

Direct peers

• Veloxis Pharmaceuticals: Veloxis (an Asahi Kasei company) is a transplant-focused specialty pharma best known for Envarsus XR, a once-daily tacrolimus formulation. It is the most direct competitor in transplant immunosuppression with overlapping prescribers (transplant centers) and a head-to-head competitive dynamic with tegoprubart.
• United Therapeutics: United Therapeutics is a leader in xenotransplantation (e.g., Revivicor/UKidney) and has a strategic collaboration with Eledon to use tegoprubart as the immunosuppression backbone for its xenotransplant programs, making it a co-developer in the same clinical and commercial pathway.
• eGenesis: eGenesis is developing gene-edited pig organs for xenotransplantation and is Eledon's strategic partner in running the tegoprubart-based immunosuppression regimen in their Phase 1/2/3 xenotransplant study. The companies are commercially and clinically co-dependent in xenotransplantation.

Emerging players

• Sangamo Therapeutics: Sangamo is developing zinc-finger nuclease gene-editing approaches for transplant tolerance, including donor-derived cell therapy programs that could compete with tegoprubart's Treg-polarizing mechanism in the transplant immunology space.

Others

• CareDx: CareDx is a transplant-focused diagnostics company (AlloSure, AlloMap) that serves the same transplant centers and nephrologists Eledon would target with tegoprubart, making it an ecosystem peer for transplant commercial strategy even though it does not compete therapeutically.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/eledon_pharma

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds9 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eledon Pharmaceuticals